Novartis Ag Stock News

Royal Fund Management LLC reduced its holdings in Novartis AG (NYSE:NVS) by 7.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,601 shares of the companys stock after selling 2,888 shares during the period. Royal Fund Management LLCs []

NEW YORK , Dec. 6, 2021 /PRNewswire/ -- Holmusk, a leading global data science and digital health company building the world''s largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round. The round included new investors Novartis (dRx Capital), Northwell Holdings, the venture investment arm of Northwell Health, and another leading healthcare corporate venture group, as well as initial investors Optum Ventures, Health Catalyst Capital and Heritas Capital. The new funding round enables Holmusk to expand its global operations, as well as deepen its investment in its proprietary technology and growth of its data asset to better harness and analyze behavioral health real-world data to accelerate drug development and data-driven medicine. "Holmusk is redefining the Electronic Health Record from a simple repository of data to an advanced clinical decision support tool underpinning the next generation of evidence in behavioral health," said Michael Weintraub , Holmusk Board Chair. "This strategic round marks an exciting milestone for Holmusk as we continue to reinvent the ways in which we care for patients with behavioral health needs." "Today''s news demonstrates industry validation of our Real-World Evidence strategy in behavioral health with the addition of leading pharma and provider players," said Nawal Roy , Holmusk Founder & CEO. "We are extremely fortunate to bring on new partners in Novartis, Northwell and others who can support our mission through their deep understanding of the importance of evidence-based care." About Holmusk Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation.

A recent analytical report on the Global "Amoxicillin Market" offers a full recap and comprehensive description of the business and also offers sophisticated knowledge about the key market players and key factors that will influence the business growth. The report

FDEU: European Equity CEF With Fully Covered 6.89% Yield And A -13.45% Discount

They are among the 12 drug companies with the most resources for acquisitions Related Stocks: MRK , JAZZ , AZN , PFE , JNJ , MRNA , BNTX , REGN , VRTX , NVS , NVO , GSK , FOLD , PTLA , AIMT , GTHX ,

Eighteen large U.S. and European drug companies will have more than $1.7 trillion in buying power by the end of 2022, according to SVB Leerink analyst Geoffrey Porges. That includes $500 billion in ca

A clinical trial is a research investigation in which individuals can participate. The intent of a clinical trial is to investigate the efficacy of a treatment, medication, experimental drug or instrument. Clinical trials in the field of neurology constitute neurology

Increasing prevalence of skin infections such as eczema and psoriasis, as well as minor diseases such as acne, is one of the factors responsible for the growth of the topical drug delivery market. Preference for drug delivery through the skin

Latest published market study on Worldwide Penicillin Drugs Market provides an overview of the current market dynamics in the Worldwide Penicillin Drugs space, as well as what our survey respondentsall outsourcing decision-makerspredict the market will look like in 2027. The

(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. The company said a

The T-Cell Immunotherapy research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the T-Cell Immunotherapy research report offers information and thoughtful

Global Neurology Clinical Trials Market: Overview Rising instances of various genetic as well as neurological disorders is driving the growth in neurology clinical trials market. The professional survey report is a holistic assessment of various micro- and macro- economic factors shaping

Among the others seeking approval are Argenx and Calliditas Related Stocks: ARGX , CALT , JNJ , MRK , NVS , TVTX , XBRU:UCB ,

Novartis said Thursday it''s interested in "bolt-on" deals and investors zeroed in on Aurinia Pharmaceuticals, sending AUPH stock flying.

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS ) and Roche Holdings AG (OTC: RHHBY ). It has added another major biotech, Astellas Pharma Inc (OTC: ALPMY ) Astellas is dishing out $18 million upfront and up to $1.6 billion in milestone and royalty payments to develop adeno-associated virus (AAV) vectors for gene Full story available on Benzinga.com